Modality
Small Molecule
MOA
STINGag
Target
PCSK9
Pathway
DDR
PTSD
Development Pipeline
Preclinical
~Aug 2021
→ ~Nov 2022
Phase 1
Feb 2023
→ Apr 2031
Phase 1Current
NCT07074946
2,652 pts·PTSD
2023-02→2031-04·Recruiting
2,652 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-04-055.0y awayInterim· PTSD
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1
Recruit…
Catalysts
Interim
2031-04-05 · 5.0y away
PTSD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07074946 | Phase 1 | PTSD | Recruiting | 2652 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 |